This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2020 Jun 23;11(25):2462-2463.

doi: 10.18632/oncotarget.27403.

Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy

Caroline M Robb¹, Smit Kour¹, Jacob I Contreras¹, Ekta Agarwal¹, Carter J Barger¹, Sandeep Rana¹, Yogesh Sonawane¹, Beth K Neilsen¹, Margaret Taylor¹, Smitha Kizhake¹, Rhishikesh N Thakare², Sanjib Chowdhury³, Jing Wang^{1

4}, Jennifer D Black^{1

4}, Michael A Hollingsworth^{1

4}, Michael G Brattain^{1

4

5}, Amarnath Natarajan^{1

2

4}

Affiliations

Affiliations

¹ Eppley Institute for Research in Cancer, University of Nebraska Medical Center, 985950 Nebraska Medical Center, Omaha, Nebraska 68198-5950, USA.
² Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska 68198-5950, USA.
³ Section of Gastroenterology, Department of Medicine, Boston University Medical Center, Boston, Massachusetts 02118, USA.
⁴ Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska 68198-5950, USA.
⁵ Deceased.

PMID: 32637035
PMCID: PMC7321697
DOI: 10.18632/oncotarget.27403

Published Erratum

Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy

Caroline M Robb et al. Oncotarget. 2020.

. 2020 Jun 23;11(25):2462-2463.

doi: 10.18632/oncotarget.27403.

Authors

Caroline M Robb¹, Smit Kour¹, Jacob I Contreras¹, Ekta Agarwal¹, Carter J Barger¹, Sandeep Rana¹, Yogesh Sonawane¹, Beth K Neilsen¹, Margaret Taylor¹, Smitha Kizhake¹, Rhishikesh N Thakare², Sanjib Chowdhury³, Jing Wang^{1

4}, Jennifer D Black^{1

4}, Michael A Hollingsworth^{1

4}, Michael G Brattain^{1

4

5}, Amarnath Natarajan^{1

2

4}

Affiliations

¹ Eppley Institute for Research in Cancer, University of Nebraska Medical Center, 985950 Nebraska Medical Center, Omaha, Nebraska 68198-5950, USA.
² Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska 68198-5950, USA.
³ Section of Gastroenterology, Department of Medicine, Boston University Medical Center, Boston, Massachusetts 02118, USA.
⁴ Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska 68198-5950, USA.
⁵ Deceased.

PMID: 32637035
PMCID: PMC7321697
DOI: 10.18632/oncotarget.27403

Abstract

[This corrects the article DOI: 10.18632/oncotarget.23749.].

Copyright: © 2019 Robb et al.

PubMed Disclaimer

Figures

Figure 3. 20-223 inhibits the kinase activity of CDK5 and CDK2 in vitro.

See this image and copyright information in PMC

Erratum for

Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.
Robb CM, Kour S, Contreras JI, Agarwal E, Barger CJ, Rana S, Sonawane Y, Neilsen BK, Taylor M, Kizhake S, Thakare RN, Chowdhury S, Wang J, Black JD, Hollingsworth MA, Brattain MG, Natarajan A. Robb CM, et al. Oncotarget. 2017 Dec 28;9(4):5216-5232. doi: 10.18632/oncotarget.23749. eCollection 2018 Jan 12. Oncotarget. 2017. PMID: 29435174 Free PMC article.

Publication types

Actions

Grants and funding

P50 CA127297/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources